Quick answer
How is AOD-9604 used in metabolic pathway research? AOD-9604, the C-terminal fragment of human growth hormone (residues 176-191 as listed on the product page), is studied as a narrow probe of lipid-handling signaling. Published work pairs it with intact growth hormone (and a related fragment, AOD-9401) and measures lipolytic and lipogenic activity in adipose tissue, β3-adrenergic receptor expression, energy expenditure and substrate oxidation, and insulin sensitivity by euglycemic clamp. The studies are tissue- and rodent-based. A well-built experiment needs a vehicle arm, an intact-hormone comparator, a lipolysis-stimulus positive control and molar-matched concentrations from the calculator. Supplied for laboratory research use only.
What the compound is, as supplied
The AOD-9604 product page lists a single 5 mg size, ≥98% HPLC purity, the molecular formula C78H123N23O23S2 (about 1.8 kDa), the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, a lyophilized supplied form and a sealed clear glass vial. Storage is refrigeration at 2-8 °C, or −20 °C for long-term, protected from heat, moisture and light. The sequence contains two cysteine residues, which makes the redox state of the buffer relevant: reducing agents change the molecule, so leave them out of diluents unless the experiment is about that.
The AOD-9604 research overview covers background and structure. This article is organized differently, by assay: what each experiment measures, which published study used it and what controls it needs.
Assay panel overview
| Assay | Question it answers | Published AOD-9604 example | System |
|---|---|---|---|
| Lipolytic activity in adipose tissue (glycerol or fatty-acid release) | Does the peptide raise breakdown of stored triglyceride? | Increased lipolytic activity in adipose tissue from exposed rats (AOD9604)[1] and from AOD-9401-exposed mice[3] | Ex vivo adipose, rodent; human adipose tissue in vitro[3] |
| Lipogenic activity | Does it lower fat synthesis? | Reduced lipogenic activity in ob/ob mouse adipose tissue (AOD-9401)[3] | Ex vivo adipose |
| β3-adrenergic receptor expression | Is a β-adrenergic route involved? | β3-AR RNA raised toward lean-mouse levels; chronic weight and lipolysis effects absent in β3-AR knock-out mice, though an acute energy-expenditure effect remained[2] | Obese and knock-out mice |
| Energy expenditure and substrate oxidation | Is overall catabolism changed? | Acute rise in energy expenditure and in glucose and fat oxidation (AOD-9401)[3]; also seen with AOD9604 in knock-out mice[2] | ob/ob mice |
| Insulin sensitivity (euglycemic clamp) | Does it spare the insulin effect that intact GH impairs? | No adverse effect on insulin sensitivity with chronic exposure[1] | Obese Zucker rats |
Each row is a separate experiment with its own controls. A single study rarely covers more than two or three of them, so a laboratory building a panel should plan the rows it can run in the same animals or cells.
Lipolysis readouts: what they measure and where they mislead
Lipolysis is the hydrolysis of stored triacylglycerol to glycerol and fatty acids. The adipocyte uses three main lipases, with hormone-sensitive lipase long regarded as the rate-limiting enzyme until adipose triglyceride lipase was identified as a major player, and lipid-droplet proteins such as perilipin shield or expose the triglyceride core.[4] The best understood hormonal regulation is the opposing control by insulin and catecholamines.[4] Lipolysis also features in discussions of lipid turnover and obesity-induced insulin resistance.[6] That biology sets three practical rules for an AOD-9604 experiment.
- Control the hormonal background. Insulin in the medium suppresses lipolysis and catecholamines stimulate it, so serum, insulin and any β-agonist should be fixed and stated.
- Measure both products. Triacylglycerol hydrolysis releases both glycerol and non-esterified fatty acids,[4] and the two readouts do not have to move together, so report which one was measured.
- Normalize. Express release per cell number, protein or tissue mass; unnormalized readouts drift with plating density and explant size.
A positive control with a classic lipolytic stimulus defines the dynamic range of the assay. If the peptide's effect is small next to that range, it needs enough replicates to be seen.
The β3-adrenergic hypothesis and how it was tested
Heffernan and colleagues administered human GH and AOD9604 to obese mice by intraperitoneal route for 14 days and reported reductions in body weight and body fat that correlated with increased expression of β3-adrenergic receptor RNA, the major lipolytic receptor in fat cells, with both agents raising the repressed β3-AR levels in obese mice to levels comparable with those in lean mice.[2] The knock-out experiment followed: long-term exposure of β3-AR knock-out mice with hGH and AOD9604 failed to produce the change in body weight and the increase in lipolysis seen in wild-type control mice, yet in an acute experiment AOD9604 still increased energy expenditure and fat oxidation in the knock-out mice. The authors concluded that the lipolytic actions of both agents are not mediated directly through the β3-AR, although both increase its expression, which may contribute to enhanced lipolytic sensitivity.[2]
That is an example of a genetic loss-of-function control doing work a pharmacological one cannot, and its outcome was nuanced rather than simply positive. A laboratory without knock-out animals can approximate the logic with a β-adrenergic antagonist arm in adipocyte cultures, but that is a different experiment with its own off-target caveats, and published conclusions apply to the animals in the study.
Oral and intraperitoneal studies in rodent obesity models
| Study | Species | Route as reported | Duration | Reported readouts |
|---|---|---|---|---|
| Ng 2000[1] | Obese Zucker rats | Oral (AOD9604) | 19 days | Lower body-weight gain than control; higher adipose lipolytic activity; euglycemic clamp showed no adverse effect on insulin sensitivity |
| Heffernan 2000[3] (peptide AOD-9401, a related hGH fragment) | C57BL/6J ob/ob mice; rodent and human adipose tissue | Oral | 30 days | Lower body-weight gain from day 16 onward with unchanged food consumption; lower lipogenic and higher lipolytic activity ex vivo; higher energy expenditure and glucose and fat oxidation |
| Heffernan 2001[2] | Obese mice and β3-AR knock-out mice | Intraperitoneal | 14 days | Body weight and fat reductions linked to β3-AR RNA; chronic effect absent in knock-out mice |
One caution first: the 2000 mouse study used a related hGH fragment designated AOD-9401, so its findings are cited here as context for the fragment class and not as AOD9604 data. Two features of these designs deserve attention. Food consumption did not differ between exposed and control ob/ob mice in the 30-day study, which is a necessary control for any metabolic-rate claim.[3] And the insulin-sensitivity result is an explicit comparison with intact hGH, which the authors reported has an adverse effect on insulin sensitivity under chronic exposure, in contrast to AOD9604.[1] The reason a fragment is studied beside the intact hormone is precisely this contrast, so any new study of the fragment should keep an intact-hormone arm if the question is selectivity.
Concentration arithmetic, formula only
Published rodent studies report amounts per kilogram of body weight; cell and tissue assays work in molar concentration. Converting between them is a modeling exercise, not a recommendation, and no conversion is offered here. For stocks, the formula is:
concentration (mol/L) = [mass of peptide (mg) ÷ molecular weight (g/mol)] ÷ volume of diluent (mL), then × 1,000 to express in mmol/L.
For this compound the formula weight is about 1,815 g/mol. The vial mass is fixed, so volume only sets concentration; use the reconstitution calculator and write the numbers down before preparation. Net peptide content is lower than vial mass because counterions and water also occupy mass, which is why understanding HPLC purity matters when a molar claim is made.
Controls that make AOD-9604 data interpretable
- Vehicle arm identical in diluent and handling.
- Intact hGH arm, to test the fragment's selectivity claim, as in the clamp comparison above.[1]
- Positive lipolysis control with a known stimulus, to define assay range.
- Genetic or pharmacological β3 control if a β-adrenergic mechanism is the question.[2]
- Pair-fed or intake-matched controls in animal work, because food consumption confounds energy-balance readouts.[3]
- Standardized metabolic tests. Consortium guidelines describe how to design and report glucose-homeostasis tests in mice, including clamp-type procedures, and following them makes results comparable across laboratories.[5]
Handling and documentation
Reconstitute with the same diluent and stock concentration for every arm, divide leftover stock into single-use portions and keep them at the product page's storage tier, and avoid repeated freeze-thaw. Step-by-step reasoning is in how to reconstitute a lyophilized peptide. Compare the lot with its entry in the COA library where one is published; AOD-9604 purity testing explains the HPLC fields. All material discussed here is supplied for laboratory research use only; not for human or animal consumption, and not a drug, food or cosmetic.
Related reading
- AOD-9604 research overview: the pillar guide
- AOD-9604 product page: size, purity and storage line
- AOD-9604 vs hGH fragment 176-191: research comparison
- AOD-9604 peptide explained
- AOD-9604 purity testing
- Understanding HPLC purity
- How to reconstitute a lyophilized peptide
- Browse all research compounds
Frequently asked questions
What does AOD-9604 consist of?
The product page lists the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, a growth-hormone 176-191 fragment, with the formula C78H123N23O23S2 and ≥98% HPLC purity.
Which assays have been used with AOD-9604?
Ex vivo lipolysis and lipogenesis in adipose tissue, β3-adrenergic receptor RNA expression, energy expenditure and substrate oxidation, and euglycemic clamp studies, in rodent models; human adipose tissue was used in vitro in a study of the related fragment AOD-9401.[1][2][3]
Why was a β3-AR knock-out mouse used?
To test whether β3-AR is required. The chronic changes in body weight and lipolysis seen in wild-type mice did not appear in knock-out mice, but an acute energy-expenditure effect remained, and the authors concluded the actions are not mediated directly through β3-AR.[2]
Does AOD-9604 affect insulin sensitivity in these studies?
In obese Zucker rats, chronic AOD9604 showed no adverse effect on insulin sensitivity by euglycemic clamp, unlike chronic exposure with intact hGH, according to the authors.[1]
Why include intact growth hormone as a comparator?
Because the reason to study the fragment is its reported separation of lipid effects from other hormone effects. Only a side-by-side arm can test that.
Why measure glycerol as well as fatty acids?
Triglyceride hydrolysis releases both glycerol and non-esterified fatty acids,[4] and the two readouts need not move together, so measuring both and stating which is reported gives a fuller picture.
Do the published studies justify conclusions about people?
No. They are rodent and tissue studies, and this article describes them only as published preclinical work.
How is the vial stored?
Per the product page: 2-8 °C, or −20 °C for long-term, protected from heat, moisture and light.
How are concentrations calculated?
Mass in mg divided by molecular weight in g/mol gives mmol; divide by the diluent volume in mL for mol/L. The calculator does the arithmetic.
Is AOD-9604 intended for people or animals?
No. It is supplied for laboratory research use only; not for human or animal consumption.
Related reading: AOD-9604 History and Lab Synthesis from hGH Fragments, AOD-9604 Adipocyte Mechanisms: What In Vitro Data Show.
References
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. doi:10.1159/000053183 PMID: 11146367
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001. doi:10.1210/endo.142.12.8522 PMID: 11713213
- Heffernan M, et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000. doi:10.1152/ajpendo.2000.279.3.e501 PMID: 10950816
- Lafontan M, et al. Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res. 2009. doi:10.1016/j.plipres.2009.05.001 PMID: 19464318
- Ayala JE, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010. doi:10.1242/dmm.006239 PMID: 20713647
- Arner P, et al. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol Metab. 2014. doi:10.1016/j.tem.2014.03.002
